These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12419746)

  • 1. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
    Merlin JL; Barberi-Heyob M; Bachmann N
    Ann Oncol; 2002 Nov; 13(11):1743-8. PubMed ID: 12419746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
    Slamon D; Pegram M
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
    Burris HA
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
    Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
    J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The platinum agents: a role in breast cancer treatment?
    Crown JP
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):28-37. PubMed ID: 11301372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
    Burris HA
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
    Montemurro F; Choa G; Faggiuolo R; Sperti E; Capaldi A; Donadio M; Minischetti M; Salomone A; Vietti-Ramus G; Alabiso O; Aglietta M
    Am J Clin Oncol; 2003 Feb; 26(1):95-7. PubMed ID: 12576933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trials of new combinations of Herceptin in metastatic breast cancer.
    Thomssen C
    Anticancer Drugs; 2001 Dec; 12 Suppl 4():S19-25. PubMed ID: 11989523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
    Ficorella C
    Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
    Gori S; Colozza M; Mosconi AM; Franceschi E; Basurto C; Cherubini R; Sidoni A; Rulli A; Bisacci C; De Angelis V; Crinò L; Tonato M
    Br J Cancer; 2004 Jan; 90(1):36-40. PubMed ID: 14710203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab/chemotherapy combinations in metastatic breast cancer.
    Ligibel JA; Winer EP
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
    Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
    J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression.
    Menendez JA; Ropero S; Lupu R; Colomer R
    Oncol Rep; 2004 Jun; 11(6):1241-52. PubMed ID: 15138562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.
    Ladoire S; Arnould L; Mignot G; Apetoh L; Rébé C; Martin F; Fumoleau P; Coudert B; Ghiringhelli F
    Br J Cancer; 2011 Jul; 105(3):366-71. PubMed ID: 21750556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.